BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han Z, Li W. Enhancer RNA: What we know and what we can achieve. Cell Prolif 2022;:e13202. [PMID: 35170113 DOI: 10.1111/cpr.13202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Panahi-Moghadam S, Hassani S, Farivar S, Vakhshiteh F. Emerging Role of Enhancer RNAs as Potential Diagnostic and Prognostic Biomarkers in Cancer. Noncoding RNA 2022;8:66. [PMID: 36287118 DOI: 10.3390/ncrna8050066] [Reference Citation Analysis]
2 Wang Y, Zhang C, Wang Y, Liu X, Zhang Z. Enhancer RNA (eRNA) in Human Diseases. Int J Mol Sci 2022;23:11582. [PMID: 36232885 DOI: 10.3390/ijms231911582] [Reference Citation Analysis]
3 Wang L, Zhou S, Zhou Y, Lu J, Wang F. A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma. Journal of Immunology Research 2022;2022:1-18. [DOI: 10.1155/2022/8069858] [Reference Citation Analysis]
4 Napoli S, Munz N, Guidetti F, Bertoni F. Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades. Cancers 2022;14:1978. [DOI: 10.3390/cancers14081978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]